131 related articles for article (PubMed ID: 38570266)
21. Characterisation of GATA3 expression in invasive breast cancer: differences in histological subtypes and immunohistochemically defined molecular subtypes.
Shaoxian T; Baohua Y; Xiaoli X; Yufan C; Xiaoyu T; Hongfen L; Rui B; Xiangjie S; Ruohong S; Wentao Y
J Clin Pathol; 2017 Nov; 70(11):926-934. PubMed ID: 28428285
[TBL] [Abstract][Full Text] [Related]
22. GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas.
Cimino-Mathews A; Subhawong AP; Illei PB; Sharma R; Halushka MK; Vang R; Fetting JH; Park BH; Argani P
Hum Pathol; 2013 Jul; 44(7):1341-9. PubMed ID: 23375642
[TBL] [Abstract][Full Text] [Related]
23. Young investigator challenge: The utility of GATA3 immunohistochemistry in the evaluation of metastatic breast carcinomas in malignant effusions.
Lew M; Pang JC; Jing X; Fields KL; Roh MH
Cancer Cytopathol; 2015 Oct; 123(10):576-81. PubMed ID: 26465236
[TBL] [Abstract][Full Text] [Related]
24. Combined use of SOX10 and GATA3 in mammary carcinoma.
Qazi MS; McGregor SM
Pathol Res Pract; 2020 Feb; 216(2):152801. PubMed ID: 31924335
[TBL] [Abstract][Full Text] [Related]
25. Expression patterns of GATA3 and the androgen receptor are strongly correlated in patients with triple-negative breast cancer.
Kim S; Moon BI; Lim W; Park S; Cho MS; Sung SH
Hum Pathol; 2016 Sep; 55():190-5. PubMed ID: 27184484
[TBL] [Abstract][Full Text] [Related]
26. Comparison of metastatic neuroendocrine neoplasms to the breast and primary invasive mammary carcinomas with neuroendocrine differentiation.
Mohanty SK; Kim SA; DeLair DF; Bose S; Laury AR; Chopra S; Mertens RB; Dhall D
Mod Pathol; 2016 Aug; 29(8):788-98. PubMed ID: 27125358
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic utility and sensitivities of GATA3 antibodies in triple-negative breast cancer.
Krings G; Nystrom M; Mehdi I; Vohra P; Chen YY
Hum Pathol; 2014 Nov; 45(11):2225-32. PubMed ID: 25150746
[TBL] [Abstract][Full Text] [Related]
28. Significantly increased PELP1 protein expression in primary and metastatic triple-negative breast carcinoma: comparison with GATA3 expression and PELP1's potential role in triple-negative breast carcinoma.
Dang DN; Raj G; Sarode V; Molberg KH; Vadlamudi RK; Peng Y
Hum Pathol; 2015 Dec; 46(12):1829-35. PubMed ID: 26428280
[TBL] [Abstract][Full Text] [Related]
29. Utility of TRPS-1 immunohistochemistry in diagnosis of metastatic breast carcinoma in cytology specimens.
Abdelwahed M; Yurtsever N; Savant D; Karam P; Gimenez C; Das K; Sheikh-Fayyaz S; Khutti S
J Am Soc Cytopathol; 2022; 11(6):345-351. PubMed ID: 36055933
[TBL] [Abstract][Full Text] [Related]
30. Sry-related high-mobility-group/HMG box 10 (SOX10) as a sensitive marker for triple-negative breast cancer.
Jamidi SK; Hu J; Aphivatanasiri C; Tsang JY; Poon IK; Li JJ; Chan SK; Cheung SY; Tse GM
Histopathology; 2020 Dec; 77(6):936-948. PubMed ID: 32304249
[TBL] [Abstract][Full Text] [Related]
31. A combination of GATA3 and SOX10 is useful for the diagnosis of metastatic triple-negative breast cancer.
Tozbikian GH; Zynger DL
Hum Pathol; 2019 Mar; 85():221-227. PubMed ID: 30468800
[TBL] [Abstract][Full Text] [Related]
32. GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens.
Shield PW; Papadimos DJ; Walsh MD
Cancer Cytopathol; 2014 Apr; 122(4):307-12. PubMed ID: 24421220
[TBL] [Abstract][Full Text] [Related]
33. The Novel Marker GATA3 is Significantly More Sensitive Than Traditional Markers Mammaglobin and GCDFP15 for Identifying Breast Cancer in Surgical and Cytology Specimens of Metastatic and Matched Primary Tumors.
Sangoi AR; Shrestha B; Yang G; Mego O; Beck AH
Appl Immunohistochem Mol Morphol; 2016 Apr; 24(4):229-37. PubMed ID: 25906123
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of androgen receptor and GATA binding protein 3 as immunohistochemical markers in the diagnosis of metastatic breast carcinoma to the lung.
Hattori Y; Yoshida A; Yoshida M; Takahashi M; Tsuta K
Pathol Int; 2015 Jun; 65(6):286-92. PubMed ID: 25727644
[TBL] [Abstract][Full Text] [Related]
35. Differences in GATA3 expression among histological/molecular subtypes and grades in infiltrating breast carcinoma (IBC) are important in the diagnosis of metastatic breast carcinoma.
Stolnicu S; Tunde C; Cadar A; Boros M
Pol J Pathol; 2020; 71(1):62-65. PubMed ID: 32429656
[TBL] [Abstract][Full Text] [Related]
36. GATA3 expression in clinically useful groups of breast carcinoma: a comparison with GCDFP15 and mammaglobin for identifying paired primary and metastatic tumors.
Yang Y; Lu S; Zeng W; Xie S; Xiao S
Ann Diagn Pathol; 2017 Feb; 26():1-5. PubMed ID: 28038704
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of TRPS1 Expression in Pleural Effusion Cytology Specimens With Metastatic Breast Carcinoma.
Wang M; Stendahl K; Cai G; Adeniran A; Harigopal M; Gilani SM
Am J Clin Pathol; 2022 Sep; 158(3):416-425. PubMed ID: 35760555
[TBL] [Abstract][Full Text] [Related]
38. Combined SOX10 GATA3 is most sensitive in detecting primary and metastatic breast cancers: a comparative study of breast markers in multiple tumors.
Aphivatanasiri C; Li J; Chan R; Jamidi SK; Tsang JY; Poon IK; Shao Y; Tong J; To KF; Chan SK; Tam F; Cheung SY; Shea KH; Tse GM
Breast Cancer Res Treat; 2020 Nov; 184(1):11-21. PubMed ID: 32737715
[TBL] [Abstract][Full Text] [Related]
39. Utility of different immunostains for diagnosis of metastatic breast carcinomas in both surgical and cytological specimens.
Hou Y; Shen R; Chaudhary S; Tonkovich D; Li Z
Ann Diagn Pathol; 2017 Oct; 30():21-27. PubMed ID: 28965624
[TBL] [Abstract][Full Text] [Related]
40. Association of TRPS1 gene with different EMT markers in ERα-positive and ERα-negative breast cancer.
Su P; Hu J; Zhang H; Jia M; Li W; Jing X; Zhou G
Diagn Pathol; 2014 Jun; 9():119. PubMed ID: 24934762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
